

Global Endometriosis Therapeutics Market - 2025 -2033

<https://marketpublishers.com/r/G9A4D786A693EN.html>

Date: October 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G9A4D786A693EN

Abstracts

Global Endometriosis Therapeutics Market: Industry Outlook

The global endometriosis therapeutics market reached US\$ 1.44 billion in 2023, with a rise of US\$ 1.59 billion in 2024, and is expected to reach US\$ 4.05 billion by 2033, growing at a CAGR of 10.6% during the forecast period 2025-2033.

The global endometriosis therapeutics market is experiencing significant growth due to increased awareness of women's reproductive health, increased diagnosis rates, and the introduction of advanced treatment options. The market is being reshaped by novel oral gonadotropin-releasing hormone antagonists, established hormonal therapies, and long-acting GnRH agonists. Despite challenges like high treatment costs and side effects, leading pharmaceutical companies and emerging biotech players are expanding product portfolios, enhancing patient compliance, and investing in disease-modifying research. North America leads the market due to early adoption of innovative therapies, while Asia-Pacific is expected to experience the fastest growth.

Dynamics: Drivers & Restraints

Driver: Rising Prevalence of Endometriosis

The global increase in endometriosis cases is driving market expansion due to increased demand for effective treatment options. Increased awareness among women, improved diagnostic capabilities, and broader healthcare access have led to earlier detection and more patients seeking medical intervention. This has prompted pharmaceutical companies to develop innovative therapies for symptom management and long-term disease control.

For instance, endometriosis is a painful gynaecological condition affecting over 190 million girls and women globally. India alone represents 25 percent of the burden with an estimated 43 million women enduring the pain.

Restraint: High Developmental Costs

The high costs of research, development, and commercialization of new endometriosis therapeutics, particularly hormonal modulators and biologics, pose a significant market challenge. These expenses often result in high drug prices, limiting accessibility in cost-sensitive regions and burdening healthcare systems, slowing adoption rates and restricting market penetration, especially in developing economies.

For instance, endometriosis surgery in the U.S. is typically expensive, ranging from \$15,000 to \$60,000 or more. The cost can vary based on factors like surgery Therapeutic Type, hospital, and insurance coverage. Despite the availability of advanced medical technology and skilled surgeons, the cost of care remains a significant concern.

Segmentation Analysis

The global endometriosis therapeutics market is segmented based on therapeutic type, route of administration, distribution channel, and region.

Therapeutic Type:

The hormone therapy from the therapeutic type segment is expected to have 57.81% of the endometriosis therapeutics market share.

Hormone-therapy plays a significant role in the global endometriosis therapeutics market due to various clinical, commercial, and patient-centric factors. Rising diagnostic rates have expanded the treated population, which prefers medical over surgical management. Newer oral GnRH-antagonist regimens and improved progestin/LNG-IUS formulations offer long-term symptom control and fertility-preserving care.

For instance, in March 2025, the NHS in England has approved Gedeon Richter's Ryeqo, the first long-term pill for endometriosis, marking a significant breakthrough in treatment, but only for patients who have tried all other options.

Moreover, clinical guidelines increasingly endorse stepped medical therapy before or after conservative surgery, promoting hormonal maintenance. Cost-effective, outpatient hormonal strategies are preferred by payers and health systems, improving reimbursement and uptake. Patient demand for non-invasive treatments sustains investment in formulation innovation and delivery systems.

Geographical Share Analysis

The North America global endometriosis therapeutics market was valued at 42.1% market share in 2024

The North American endometriosis therapeutics market is experiencing growth due to a high diagnosed patient pool, improved access to gynecological care, leading pharmaceutical companies, favorable reimbursement frameworks, FDA approvals, orphan drug incentives, robust clinical research infrastructure, and a cultural emphasis on early diagnosis, fertility preservation, and quality-of-life improvement. This has led to faster adoption of innovative treatment regimens and sustained demand for first-line and maintenance treatments.

For instance, in January 2025, Celmatix Therapeutics announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The therapeutic drug candidate, developed using the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM), aims to address a critical unmet need in first-line treatments for a range of women's health indications, starting with endometriosis and potentially extending to Polycystic Ovary Syndrome (PCOS) and ovarian aging.

Major Players

The major players in the endometriosis therapeutics market include Bayer AG, AbbVie, Inc, Pfizer Inc, Gedeon Richter Plc, Teva Pharmaceuticals, Theramex, Tiumbio, and TerSera Therapeutics LLC and among others.

Key Developments

In July 2025, Staffordshire hospital trust, University Hospitals of North Midlands NHS Trust, has been awarded ?250,000 to study a new method for treating endometriosis. The two-year project, run in partnership with Birmingham Women's and Children's NHS Foundation Trust, aims to improve patient

treatment for 70 patients across two sites.

The global endometriosis therapeutics market report delivers a detailed analysis with 59 key tables, more than 56 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Therapeutic Type
- 2.4. Snippet by Route of Administration
- 2.5. Snippet by Distribution Channel
- 2.6. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Prevalence of Endometriosis
 - 3.1.1.2. Increase in Minimally Invasive Surgical Techniques
 - 3.1.2. Restraints
 - 3.1.2.1. High Developmental Costs
 - 3.1.2.2. Side Effects of Therapies
 - 3.1.3. Opportunity
 - 3.1.3.1. Emerging Markets Expansion
 - 3.1.3.2. Personalized Medicine Adoption
 - 3.1.4. Impact Analysis

4. GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established leaders with largest largest-selling Brand
 - 4.1.3. Market leaders with established products & Services
- 4.2. Product Developments and Breakthroughs

4.3. Regulatory and Reimbursement Landscape

4.3.1. North America

4.3.2. Europe

4.3.3. Asia Pacific

4.3.4. South America

4.3.5. Middle East & Africa

4.4. Porter's Five Force Analysis

4.5. Supply Chain Analysis

4.6. Patent Analysis

4.7. SWOT Analysis

4.8. Unmet Needs and Gaps

4.9. Recommended Strategies for Market Entry and Expansion

4.10. Pricing Analysis and Price Dynamics

5. GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET: BY THERAPEUTIC TYPE

5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Type

5.1.2. Market Attractiveness Index, By Therapeutic Type

5.2. Pain Medicines*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.3. Hormone Therapy

5.3.1. Hormonal Contraceptives

5.3.2. Gonadotropin-releasing hormone (Gn-RH) Agonists and Antagonists

5.3.3. Progestin Therapy

6. GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

6.1.2. Market Attractiveness Index, By Route of Administration

6.2. Oral*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Injectable

6.4. Others

7. GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

7.1.2. Market Attractiveness Index, By Distribution Channel

7.2. Hospital Pharmacies*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Retail Pharmacies

7.4. Online Pharmacies

8. GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9. INTRODUCTION

9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.1. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. U.K.

9.3.6.3. France

9.3.6.4. Spain

9.3.6.5. Italy

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

- 11.1. Market Share Analysis and Positioning Matrix
- 11.2. Strategic Partnerships, Mergers & Acquisitions
- 11.3. Key Developments in Product Portfolios and Innovations
- 11.4. Company Benchmarking

12. COMPANY PROFILES

- 12.1. Bayer AG*
 - 12.1.1. Company Overview
 - 12.1.1.1. Product Portfolio
 - 12.1.1.2. Product Description
 - 12.1.1.3. Product Key Performance Indicators (KPIs)
 - 12.1.1.4. Historic and Forecasted Product Sales
 - 12.1.1.5. Product Sales Volume
 - 12.1.2. Financial Overview
 - 12.1.2.1. Company Revenue
 - 12.1.2.2. Geographical Revenue Shares
 - 12.1.2.3. Revenue Forecasts
 - 12.1.3. Key Developments
 - 12.1.3.1. Mergers & Acquisitions
 - 12.1.3.2. Key Product Development Activities
 - 12.1.3.3. Regulatory Approvals, etc.
 - 12.1.3.4. SWOT Analysis
- 12.2. AbbVie, Inc
- 12.3. Pfizer Inc
- 12.4. Gedeon Richter Plc
- 12.5. Teva Pharmaceuticals
- 12.6. Theramex
- 12.7. Tiumbio
- 12.8. TerSera Therapeutics LLC (LIST NOT EXHAUSTIVE)

13. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 13.1. Data Collection Methods
- 13.2. Data Triangulation
- 13.3. Forecasting Techniques

13.4. Data Verification and Validation

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 Global Endometriosis Therapeutics Market Value, By Therapeutic Type, 2025, 2029 & 2033 (US\$ Billion)

Table 2 Global Endometriosis Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Billion)

Table 3 Global Endometriosis Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US\$ Billion)

Table 4 Global Endometriosis Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 5 Global Endometriosis Therapeutics Market Value, By Therapeutic Type, 2025, 2029 & 2033 (US\$ Billion)

Table 6 Global Endometriosis Therapeutics Market Value, By Therapeutic Type, 2022-2033 (US\$ Billion)

Table 7 Global Endometriosis Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Billion)

Table 8 Global Endometriosis Therapeutics Market Value, By Route of Administration, 2022-2033 (US\$ Billion)

Table 9 Global Endometriosis Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US\$ Billion)

Table 10 Global Endometriosis Therapeutics Market Value, By Distribution Channel, 2022-2033 (US\$ Billion)

Table 11 Global Endometriosis Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)

Table 12 Global Endometriosis Therapeutics Market Value, By Region, 2022-2033 (US\$ Billion)

Table 13 North America Endometriosis Therapeutics Market Value, By Therapeutic Type, 2022-2033 (US\$ Billion)

Table 14 North America Endometriosis Therapeutics Market Value, By Route of Administration, 2022-2033 (US\$ Billion)

Table 15 North America Endometriosis Therapeutics Market Value, By Distribution Channel, 2022-2033 (US\$ Billion)

Table 16 North America Endometriosis Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 17 Europe Endometriosis Therapeutics Market Value, By Therapeutic Type, 2022-2033 (US\$ Billion)

Table 18 Europe Endometriosis Therapeutics Market Value, By Route of Administration,

2022-2033 (US\$ Billion)

Table 19 Europe Endometriosis Therapeutics Market Value, By Distribution Channel, 2022-2033 (US\$ Billion)

Table 20 Europe Endometriosis Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 21 Asia-Pacific Endometriosis Therapeutics Market Value, By Therapeutic Type, 2022-2033 (US\$ Billion)

Table 22 Asia-Pacific Endometriosis Therapeutics Market Value, By Route of Administration, 2022-2033 (US\$ Billion)

Table 23 Asia-Pacific Endometriosis Therapeutics Market Value, By Distribution Channel, 2022-2033 (US\$ Billion)

Table 24 Asia-Pacific Endometriosis Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 25 South America Endometriosis Therapeutics Market Value, By Therapeutic Type, 2022-2033 (US\$ Billion)

Table 26 South America Endometriosis Therapeutics Market Value, By Route of Administration, 2022-2033 (US\$ Billion)

Table 27 South America Endometriosis Therapeutics Market Value, By Distribution Channel, 2022-2033 (US\$ Billion)

Table 28 South America Endometriosis Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 29 Middle East and Africa Endometriosis Therapeutics Market Value, By Therapeutic Type, 2022-2033 (US\$ Billion)

Table 30 Middle East and Africa Endometriosis Therapeutics Market Value, By Route of Administration, 2022-2033 (US\$ Billion)

Table 31 Middle East and Africa Endometriosis Therapeutics Market Value, By Distribution Channel, 2022-2033 (US\$ Billion)

Table 32 Middle East and Africa Endometriosis Therapeutics Market Value, By Country, 2022-2033 (US\$ Billion)

Table 33 Bayer AG: Overview

Table 34 Bayer AG: Product Portfolio

Table 35 Bayer AG: Key Developments

Table 36 AbbVie, Inc: Overview

Table 37 AbbVie, Inc: Product Portfolio

Table 38 AbbVie, Inc: Key Developments

Table 39 Pfizer Inc: Overview

Table 40 Pfizer Inc: Product Portfolio

Table 41 Pfizer Inc: Key Developments

Table 42 Gedeon Richter Plc: Overview

- Table 43 Gedeon Richter Plc: Product Portfolio
- Table 44 Gedeon Richter Plc: Key Developments
- Table 45 Teva Pharmaceuticals: Overview
- Table 46 Teva Pharmaceuticals: Product Portfolio
- Table 47 Teva Pharmaceuticals: Key Developments
- Table 48 Theramex: Overview
- Table 49 Theramex: Product Portfolio
- Table 50 Theramex: Key Developments
- Table 51 Tiumbio: Overview
- Table 52 Tiumbio: Product Portfolio
- Table 53 Tiumbio: Key Developments
- Table 54 TerSera Therapeutics LLC: Overview
- Table 55 TerSera Therapeutics LLC: Product Portfolio
- Table 56 TerSera Therapeutics LLC: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 2 Global Endometriosis Therapeutics Market Share, By Therapeutic Type, 2024 & 2033 (%)

Figure 3 Global Endometriosis Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Endometriosis Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Endometriosis Therapeutics Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Endometriosis Therapeutics Market Y-o-Y Growth, By Therapeutic Type, 2023-2033 (%)

Figure 7 Pain Medicines Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 8 Hormone Therapy Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 9 Global Endometriosis Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 10 Oral Route of Administration in Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 11 Injectable Route of Administration in Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 12 Others Route of Administration in Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 13 Global Endometriosis Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 14 Hospital Pharmacies Distribution Channel in Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 15 Retail Pharmacies Distribution Channel in Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 16 Online Pharmacies Distribution Channel in Global Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 17 Global Endometriosis Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 18 North America Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 19 North America Endometriosis Therapeutics Market Share, By Therapeutic Type, 2024 & 2033 (%)

Figure 20 North America Endometriosis Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 21 North America Endometriosis Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 22 North America Endometriosis Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 23 Europe Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 24 Europe Endometriosis Therapeutics Market Share, By Therapeutic Type, 2024 & 2033 (%)

Figure 25 Europe Endometriosis Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 26 Europe Endometriosis Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 27 Europe Endometriosis Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 28 Asia-Pacific Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 29 Asia-Pacific Endometriosis Therapeutics Market Share, By Therapeutic Type, 2024 & 2033 (%)

Figure 30 Asia-Pacific Endometriosis Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 31 Asia-Pacific Endometriosis Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 32 Asia-Pacific Endometriosis Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 33 South America Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 34 South America Endometriosis Therapeutics Market Share, By Therapeutic Type, 2024 & 2033 (%)

Figure 35 South America Endometriosis Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 36 South America Endometriosis Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 37 South America Endometriosis Therapeutics Market Share, By Country, 2024 & 2033 (%)

Figure 38 Middle East and Africa Endometriosis Therapeutics Market Value, 2022-2033 (US\$ Billion)

Figure 39 Middle East and Africa Endometriosis Therapeutics Market Share, By Therapeutic Type, 2024 & 2033 (%)

Figure 40 Middle East and Africa Endometriosis Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 41 Middle East and Africa Endometriosis Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Bayer AG: Financials

Figure 43 AbbVie, Inc: Financials

Figure 44 Pfizer Inc: Financials

Figure 45 Gedeon Richter Plc: Financials

Figure 46 Teva Pharmaceuticals: Financials

Figure 47 Theramex: Financials

Figure 48 Tiumbio: Financials

Figure 49 TerSera Therapeutics LLC: Financials

I would like to order

Product name: Global Endometriosis Therapeutics Market - 2025 -2033

Product link: <https://marketpublishers.com/r/G9A4D786A693EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9A4D786A693EN.html>